New treatment for cancer using dual inhibitors targeting tumor cells and boosting immune response
MERTK/AXL dual inhibitors provide novel treatment for cancer by targeting tumor cells and activating anti-tumor immunity
['FUNDING_R01'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-10837815
This study is looking at new treatments that block two proteins linked to cancer growth, which could help kill cancer cells and boost your immune system's ability to fight tumors, and patients may have a chance to join trials testing these promising therapies.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-10837815 on ClinicalTrials.gov |
What this research studies
This research investigates the use of dual inhibitors targeting MERTK and AXL, two proteins that are often overexpressed in cancer cells and contribute to tumor growth and resistance to treatments. By inhibiting these proteins, the research aims to not only kill cancer cells directly but also enhance the body's immune response against tumors. The approach involves developing small molecule inhibitors and antibodies that can be tested in clinical trials to assess their effectiveness in treating various cancers, including non-small cell lung cancer. Patients may have the opportunity to participate in trials evaluating these novel therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with cancers that express MERTK and AXL, particularly those who have not responded well to standard treatments.
Not a fit: Patients with cancers that do not express MERTK or AXL may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that overcome resistance to existing therapies and improve patient outcomes.
How similar studies have performed: Other research has shown promising results with similar dual inhibition strategies, indicating potential for success in this approach.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, XIAODONG — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: WANG, XIAODONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer, Epithelial cancer